Core Insights - Clearmind Medicine Inc. has launched its Electronic Data Capture (EDC) system to support its Phase I/II clinical trial for a MEAI-based treatment targeting Alcohol Use Disorder (AUD) [1][2][5] - The EDC system is designed for real-time, secure data collection and monitoring across all trial sites, ensuring compliance and integrity of the study [2][3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly alcohol use disorder [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [7] Clinical Trial Details - The clinical trial aims to evaluate the safety, tolerability, and efficacy of Clearmind's MEAI-based compound in individuals with AUD [1][2] - The EDC system includes features such as automated edit checks, real-time validation, and a secure randomization process to enhance data accuracy and compliance [3][4]
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment